Please login to the form below
Hetlioz
This page shows the latest Hetlioz news and features for those working in and with pharma, biotech and healthcare.
BMS' Opdivo backed as melanoma therapy in EU
Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -
Latest news
-
FDA approves sleep disorder drug for blind people
Vanda Pharmaceuticals wins backing for Hetlioz to improve a person’s body clock. ... This means Vanda was able to take advantage of a number of development incentives due to the orphan-drug designation for Hetlioz.
-
FDA panel backs sleep pattern drug for blind
Vanda’s Hetlioz intended to improve circadian rhythms in people who cannot see. ... A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- New study identifies drugs that are safe to use in COVID-19 treatment
- How will the events and exhibitions industry change post-Coronavirus?
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- Roche’s Tecentriq combo scores FDA approval for melanoma
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Artificial Intelligence in Digital Therapeutics
- Virtual Reality in Medicine and Clinical Research
- J&J inks $1bn deal with US for coronavirus vaccine
- Novartis builds its case for novel MS treatment ofatumumab
- Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer
- Award-winning agency Porterhouse Medical Group joins imc group with Waterland Private Equity’s support
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
